Health Canada grants approval of CytoSorb for treatment of COVID-19.- CytoSorbent

Health Canada has granted Medical Device Authorisation for the importation, sale, and emergency use of critical care immunotherapy CytoSorb, from CytoSorbent. This blood purification technology is approved to treat hospitalised Covid-19 patients under Interim Order (IO) ID no 316575. It will be commercially available in North America and 67 other countries across the world for use in Covid-19 patients. The company will partner with speciality medical products distributor in Canada, ebbtides medical, to make the treatment available rapidly and extensively. CytoSorb secured the US Food and Drug Administration (FDA) emergency use authorisation (EUA) for use in critically ill Covid-19 patients who are likely to have or confirmed respiratory failure.